At Press Time
ACA: Few immediate eye-care impacts; FDA to help speed device approvals; Eye movements slower in glaucoma patients; Time to replace SGR model; and more
By Bill Kekevian, Senior
Bright New Ideas In Glaucoma Treatment
Seven fledging companies focused on the future of lowering IOP.
By Jerry Helzner, contributing editor
Can Diet, Lifestyle Changes Really Prevent Cataracts?
The mounting and controversial evidence that modifying risk factors can prevent lens opacities.
By Sean McKinney, Contributing
Driving Optical Referrals with the MD ‘Hand-off’
Successful eyewear dispensing does not mean compromising professional principles,.
How Mobile Apps Can Streamline Operations
Selected medical apps provide easy reference, patient education, remote EMR access, etc.
By Lisa B. Samalonis, Contributing
How to Manage Post-op Residual Astigmatism
Strategies to optimize toric IOL outcomes and manage residual astigmatism after surgery.
By Jessica Shonfeld, MD, Mujtaba
How Two Surgeons Make Retinal Referrals Work
Mutual trust and frequent contact commingle with a shared priority for the patient’s best interest.
By Robert Murphy
Not What the Doctor Ordered
Restrictive formularies tie ophthalmologists’ hands and impact patient care.
By Jerry Helzner, contributing editor
Taking Drug Safety To the Next Level
Single-use guidelines and flawed compounded drugs are bringing new vigilance to ASCs.
By Virginia Pickles, Contributing
Taking IOP Measure Beyond Goldmann
Growing evidence shows NCT and other emerging approaches to measure IOP compare favorably to Goldmann tonometry.
By Karen Blum, Contributing
The Promise of Neuroprotection in Treating Glaucoma
Emerging evidence is taking a step toward putting visual preservation first in glaucoma treatment.
Think you Need a CFO? Think Again
Practitioners need help with finances, but are they spending too much for it?
Viewpoint
A perspective for 2013